Mergers & Acquisitions ·
Vertex Pharmaceuticals reported second quarter 2026 total revenue of $3.33 billion, a 12% increase from the prior year…
VRTXVertex Pharmaceuticals Inc / MA
Vertex Pharmaceuticals reported second quarter 2026 total revenue of $3.33 billion, a 12% increase from the prior year period, driven by strong performance in cystic fibrosis therapies and growth in sickle cell disease and acute pain treatments. The company raised its full-year 2026 revenue guidance to $13.1 billion–$13.2 billion from $12.95 billion–$13.1 billion, while maintaining expense guidance for combined R&D, acquired IPR&D, and SG&A at $6.3 billion–$6.45 billion (GAAP). Vertex also announced it entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, with closing anticipated in the third quarter of 2026. Additionally, the U.S. FDA assigned a PDUFA target action date of November 30, 2026, for povetacicept in IgA nephropathy. Vertex Pharmaceuticals is a global biotechnology company that develops and commercializes transformative medicines for serious diseases including cystic fibrosis, sickle cell disease, and acute pain.